Baseline characteristics of the 987 patients from the ANRS PRIMO cohort 1999–2010.

<p>TPHA = <i>Treponema palladium</i> haemagglutination assay; VDRL = Venereal Diseases Research Laboratory test; HBV = hepatits B virus; HCV = hepatitis C virus.</p

Comparison of the characteristics of patients included into clustered transmission versus non-clustered: the ANRS PRIMO cohort 1999–2010.

<p>Note: the total of patients for each variable does not always equal the total sample due to some missing values. PHI = primary HIV infection; MSM = men having sex with men; TPHA = <i>Treponema palladium</i> haemagglutination assay; VDRL = Venereal Diseases Research Laboratory test.</p>(1)<p>Urethritis, rectitis, genital herpes infection, vulvo-vaginal candidosis, condyloma and/or syphilis.</p>(2)<p>In the last 6 months preceding PHI diagnosis.</p

Severe Morbidity According to Sex in the Era of Combined Antiretroviral Therapy: The ANRS CO3 Aquitaine Cohort

<div><p>Objective</p><p>To describe trends and determinants of severe morbidity in HIV-infected women and men.</p><p>Design</p><p>A French prospective cohort of HIV-infected patients of both sexes and all transmission categories.</p><p>Methods</p><p>We used hospital admission data from January 2000 to December 2008. A severe morbid event (SME) was defined as a clinical event requiring hospitalization for ≥48 h, several events could be reported during hospitalization. Yearly incidence rates of SME were estimated and compared using Generalized Estimating Equations.</p><p>Results</p><p>Among 4,987 patients (27% women), followed for a median of 8.7 years, 1,473 (30%) were hospitalized (3,049 hospitalizations for 5,963 SME). The yearly incidence rate of hospitalization decreased in men, from 155 in 2000 to 80/1,000 person-years (PY) in 2008 and in women, from 125 to 71/1,000 PY, (p<0.001). This trend was observed for all SME except for hepatic events, stable in men (15 to 13/1,000 PY) and increasing in women (2.5 to 11.5), cardiovascular events increasing in men (6 to 10/1,000 PY) and in women (6 to 14) and non-AIDS non-hepatic malignancies increasing in men (4 to 7/1,000 PY) and stable in women (2.5). Intraveneous drug users, age >50 years, HIV RNA >10,000 copies, CD4 <500/mm³, AIDS stage, hepatitis C co-infection and cardiovascular risk factors (diabetes, high blood pressure, and tobacco use) were associated with SME.</p><p>Conclusions</p><p>HIV-infected individuals in care in France require less and less frequently hospitalization. Women are now presenting with severe hepatic and cardio-vascular events. Disparities in SME between men and women are primarily explained by different exposure patterns to risk factors. Women should be targeted to benefit cardiovascular prevention policies as well as men.</p></div

Evolution of yearly incidence rates of hospitalization according to sex (ANRS CO3 Aquitaine Cohort 2000–2008).

<p>Evolution of yearly incidence rates of hospitalization according to sex (ANRS CO3 Aquitaine Cohort 2000–2008).</p

Incidence rates of severe morbid events according to sex (ANRS CO3 Aquitaine Cohort 2000–2008).

<p>p₁ : Poisson regression test for trend, p₂ : Year*sex interaction test. Fig. 3a. AIDS events, p₁<0.001, p₂<0.001. Fig. 3b. Bacterial infections, p₁<0.01, p₂ = 0.99. Fig. 3c. Psychiatric events, p₁ = 0.25, p₂<0.005. Fig. 3d. Hepatic events, p₁ = 0.18, p₂ = 0.48. Fig. 3e. Cardiovascular events, p₁ = 0.25, p₂ = 0.83. Fig. 3f. Non-AIDS, non-hepatic malignancies, p₁ =  0.18, p₂<0.002.</p

Grid distribution.

<p>Grid distribution.</p

Factors associated with CKD in ANRS CO3 Aquitaine Cohort, N = 4350 patients and 209 cases.

<p>Results of univariable and multivariables Poisson regressions.</p><p>IRR : Incidence Rate Ratio; HBV: Hepatitis B Virus; HCV: Hepatitis C Virus.</p>*<p>With exposure to tenofovir as ever/nerver;</p>†<p>With exposure to tenofovir stratified by exposure to joint PI exposure;</p>‡<p>See <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0066223#s2" target="_blank">Methods</a> section for definition.</p

Demographic, clinical and immuno-virological characteristics according to sex, by calendar year 2000, 2004 and 2008.

<p>1.Hyper-cholesterolemia or hyper-triglyceridemia, 2. Plasma cholesterol >6.24 mmol/L or any use of lipid-lowering drugs, 3. Plasma triglycerides >2.2 mmol/L or any use of lipid-lowering drugs, 4. glycemia >7 mmol/L or any use of antidiabetic drugs, 5. Blood pressure ≥14/9 cm Hg or any use of antihypertensive drugs</p

Summarized description of viewpoints.

<p>Summarized description of viewpoints.</p

Description of persons living with HIV statements.

<p>Description of persons living with HIV statements.</p